促甲状腺激素受体
Thyroid Stimulating Hormone Receptor.
作者信息
Tuncel Murat
机构信息
Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, Turkey, Phone: +90 536 213 03 41, E-mail:
出版信息
Mol Imaging Radionucl Ther. 2017 Feb 9;26(Suppl 1):87-91. doi: 10.4274/2017.26.suppl.10.
Abstract
Thyroid stimulating hormone receptor (TSHR) plays a pivotal role in thyroid hormone metabolism. It is a major controller of thyroid cell function and growth. Mutations in TSHR may lead to several thyroid diseases, most commonly hyperthyroidism. Although its genetic and epigenetic alterations do not directly lead to carcinogenesis, it has a crucial role in tumor growth, which is initiated by several oncogenes. This article will provide a brief review of TSHR and related diseases.
摘要
促甲状腺激素受体（TSHR）在甲状腺激素代谢中起关键作用。它是甲状腺细胞功能和生长的主要调控者。TSHR的突变可能导致多种甲状腺疾病，最常见的是甲状腺功能亢进。尽管其基因和表观遗传改变不会直接导致癌变，但它在由多种癌基因引发的肿瘤生长中起关键作用。本文将简要综述TSHR及相关疾病。
相似文献
1
Thyroid Stimulating Hormone Receptor.促甲状腺激素受体
Mol Imaging Radionucl Ther. 2017 Feb 9;26(Suppl 1):87-91. doi: 10.4274/2017.26.suppl.10.
2
Clinical Significance of Thyroid-Stimulating Hormone Receptor Gene Mutations and/or Sodium-Iodine Symporter Gene Overexpression in Indeterminate Thyroid Fine Needle Biopsies.甲状腺细针穿刺活检结果不确定时促甲状腺激素受体基因突变和/或钠碘转运体基因过表达的临床意义
Front Endocrinol (Lausanne). 2018 Sep 25;9:566. doi: 10.3389/fendo.2018.00566. eCollection 2018.
3
Central dogma in thyroid dysfunction: a review on structure modification of TSHR as a cornerstone for thyroid abnormalities.甲状腺功能障碍的中心法则：关于促甲状腺激素受体结构修饰作为甲状腺异常基石的综述
Pak J Biol Sci. 2011 Feb 1;14(3):170-81. doi: 10.3923/pjbs.2011.170.181.
4
Thyroid-stimulating hormone receptor and its role in Graves' disease.促甲状腺激素受体及其在格雷夫斯病中的作用。
Mol Genet Metab. 2003 Dec;80(4):377-88. doi: 10.1016/j.ymgme.2003.09.001.
5
The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling.促甲状腺激素受体：促甲状腺激素和促甲状腺激素受体抗体对多聚化、裂解及信号传导的影响
Endocrinol Metab Clin North Am. 2009 Jun;38(2):319-41, viii. doi: 10.1016/j.ecl.2009.01.006.
6
Differential transcriptional and protein expression of thyroid-stimulating hormone receptor in ovarian carcinomas.甲状腺刺激素受体在卵巢癌中的差异转录和蛋白表达。
Int J Gynecol Cancer. 2014 Jun;24(5):851-6. doi: 10.1097/IGC.0000000000000139.
7
Cancer risk and clinicopathological characteristics of thyroid nodules harboring thyroid-stimulating hormone receptor gene mutations.携带促甲状腺激素受体基因突变的甲状腺结节的癌症风险及临床病理特征
Diagn Cytopathol. 2018 May;46(5):369-377. doi: 10.1002/dc.23915. Epub 2018 Mar 8.
8
Thyroid Stimulating Hormone Receptor Antibodies in Thyroid Eye Disease-Methodology and Clinical Applications.甲状腺眼病中的促甲状腺激素受体抗体——方法学与临床应用
Ophthalmic Plast Reconstr Surg. 2018 Jul/Aug;34(4S Suppl 1):S13-S19. doi: 10.1097/IOP.0000000000001053.
9
Constitutive activities in the thyrotropin receptor: regulation and significance.促甲状腺激素受体的组成性活性：调节与意义
Adv Pharmacol. 2014;70:81-119. doi: 10.1016/B978-0-12-417197-8.00003-1.
10
Thyrotropin receptor-associated diseases: from adenomata to Graves disease.促甲状腺激素受体相关疾病：从腺瘤到格雷夫斯病
J Clin Invest. 2005 Aug;115(8):1972-83. doi: 10.1172/JCI26031.
引用本文的文献
1
Germline predisposition in multiple myeloma.多发性骨髓瘤的种系易感性。
iScience. 2024 Dec 17;28(1):111620. doi: 10.1016/j.isci.2024.111620. eCollection 2025 Jan 17.
2
A Comprehensive Review of Thyroid Eye Disease Pathogenesis: From Immune Dysregulations to Novel Diagnostic and Therapeutic Approaches.甲状腺眼病发病机制的全面综述：从免疫失调到新的诊断和治疗方法。
Int J Mol Sci. 2024 Oct 29;25(21):11628. doi: 10.3390/ijms252111628.
3
Cryo-electron microscopy for GPCR research and drug discovery in endocrinology and metabolism.冷冻电镜在内分泌和代谢领域的 GPCR 研究和药物发现中的应用。
Nat Rev Endocrinol. 2024 Jun;20(6):349-365. doi: 10.1038/s41574-024-00957-1. Epub 2024 Feb 29.
4
G protein-coupled receptors in cochlea: Potential therapeutic targets for hearing loss.耳蜗中的G蛋白偶联受体：听力损失的潜在治疗靶点。
Front Mol Neurosci. 2022 Oct 12;15:1028125. doi: 10.3389/fnmol.2022.1028125. eCollection 2022.
5
Hormone- and antibody-mediated activation of the thyrotropin receptor.促甲状腺激素受体的激素和抗体介导的激活。
Nature. 2022 Sep;609(7928):854-859. doi: 10.1038/s41586-022-05173-3. Epub 2022 Aug 8.
6
Risk Factors of Synchronous Breast and Thyroid Cancer: a Controlled Multicenter Study and Review of the Literature.同步性乳腺癌和甲状腺癌的危险因素：一项对照多中心研究及文献综述
Mater Sociomed. 2021 Dec;33(4):298-303. doi: 10.5455/msm.2021.33.298-303.
7
Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma.分子证据显示促甲状腺激素干预会增加发生放射性碘难治性分化型甲状腺癌的风险。
Cancer Cell Int. 2022 Feb 3;22(1):61. doi: 10.1186/s12935-022-02484-3.
8
Congenital Hypothyroidism Patients With Thyroid Hormone Receptor Variants Are Not Rare: A Systematic Review.先天性甲状腺功能减退症伴甲状腺激素受体变异患者并不罕见：系统评价。
Inquiry. 2021 Jan-Dec;58:469580211067943. doi: 10.1177/00469580211067943.
9
The Role of Inositol in Thyroid Physiology and in Subclinical Hypothyroidism Management.肌醇在甲状腺生理学和亚临床甲状腺功能减退症管理中的作用。
Front Endocrinol (Lausanne). 2021 May 10;12:662582. doi: 10.3389/fendo.2021.662582. eCollection 2021.
10
Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening.用于放射性碘难治性筛查的患者来源的甲状腺乳头状癌类器官
Cancers (Basel). 2020 Oct 31;12(11):3212. doi: 10.3390/cancers12113212.
本文引用的文献
1
Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status.甲状腺癌患者中TSHR基因的表观遗传沉默与其BRAF V600E突变状态的关系。
Endocrine. 2014 Nov;47(2):449-55. doi: 10.1007/s12020-014-0319-6. Epub 2014 Jun 14.
2
Molecular pathogenesis and mechanisms of thyroid cancer.甲状腺癌的分子发病机制及机制。
Nat Rev Cancer. 2013 Mar;13(3):184-99. doi: 10.1038/nrc3431.
3
Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing.甲状腺刺激激素在 BRAF 沉默时增加甲状腺癌细胞对碘的摄取。
J Surg Res. 2013 Jun 1;182(1):85-93. doi: 10.1016/j.jss.2012.08.053. Epub 2012 Sep 8.
4
Re-induction of cell differentiation and (131)I uptake in dedifferentiated FTC-133 cell line by TSHR gene transfection.转染 TSHR 基因使去分化 FTC-133 细胞系再诱导细胞分化和（131）I 摄取。
Nucl Med Biol. 2012 Nov;39(8):1261-5. doi: 10.1016/j.nucmedbio.2012.07.004. Epub 2012 Aug 14.
5
Epigenetics modifications and therapeutic prospects in human thyroid cancer.表观遗传学修饰与人类甲状腺癌的治疗前景。
Front Endocrinol (Lausanne). 2012 Mar 19;3:40. doi: 10.3389/fendo.2012.00040. eCollection 2012.
6
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.促甲状腺激素受体信号对小鼠 BRAF 诱导甲状腺肿瘤起始的依赖性。
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1615-20. doi: 10.1073/pnas.1015557108. Epub 2011 Jan 10.
7
Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma.生长激活本身不足以在滤泡状甲状腺癌的小鼠模型中引起转移性甲状腺癌。
Endocrinology. 2010 Apr;151(4):1929-39. doi: 10.1210/en.2009-1017. Epub 2010 Feb 4.
8
Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency.人甲状腺组织中碘代谢基因的表达：年龄和BRAFV600E突变依赖性的证据。
Clin Endocrinol (Oxf). 2009 Apr;70(4):629-35. doi: 10.1111/j.1365-2265.2008.03376.x. Epub 2008 Aug 15.
9
Intragenic mutations in thyroid cancer.甲状腺癌中的基因内突变。
Endocrinol Metab Clin North Am. 2008 Jun;37(2):333-62, viii. doi: 10.1016/j.ecl.2008.02.004.
10
The comparative effects of gene modulators on thyroid-specific genes and radioiodine uptake.基因调节剂对甲状腺特异性基因和放射性碘摄取的比较效应。
Cancer Biother Radiopharm. 2007 Jun;22(3):443-9. doi: 10.1089/cbr.2006.319.A.
Zotero 插件